Timothy Bass Email & Phone Number

Ingelheim Am Rhein, Rhineland-Palatinate, De

Ingelheim Am Rhein, Rhineland-Palatinate, De

Chicago, Il, Us

Lead up to 15 internal project reports across 5 project work streams to deliver consulting engagements for small, mid-sized, and large pharma/biotechnology/medical device companies. Identify/pursue business development opportunities.CUSTOMER ENGAGEMENT: Establish trusted relationships with CEOs, Exec Directors, Sr. Directors, Chief Commercial Officers, and VPs of Portfolios, Product Planning, and Market Access. Meet with stakeholders weekly/biweekly. Manage client expectations. PROJECT LEADERSHIP: Partner with client leaders to define requirements and build details into project scope. Develop and shepherd proposals through client approval process. Lead/guide/oversee team execution. PHARMACEUTICAL LAUNCH in USA: Led medical strategy and planning for $Multi-Million dollar launch of foreign pharma company in USA multiple myeloma autologous stem cell market. Accelerated deliverables positioning asset with strong commercial value. COMPLETE COMMERCIALIZATION PROJECTS: Direct(ed) teams to deliver subprojects within large, multi-year Complete Commercialization contracts valued at $100M to $300M. Disease areas and treatment modalities include(d) autologous stem cell treatment for multiple myeloma, oral insulin for diabetes, Alzheimer’s disease, kidney disease, NSCLC, acute gout, melanoma, and other solid tumor cancers. NEGOTIATION TEAM: Member of Complete Commercialization negotiation team; SME in strategy and launch planning and roadmap. STRATEGY: Led identification of critical success factors and development of financial forecasts, commercialization strategy, and launch planning to inform commercial success, enabling clients to quickly decide on program viability and strategic approach.

Seattle, Wa, Us

Led and advised client engagements across multiple Life Sciences practices and developed service offerings for Payers, Medical Device, BioPharma, and Pharma companies. Drove business development activities and designed/sold solution engagements. Defined objective and scope of strategy engagements and client deliverables. Delivered P&L for $Multi-Million client. CLIENT SATISFACTION: Delivered client satisfaction rating of 4 out of 5 - a high rating within company known for high client satisfaction. PRIVATE EQUITY LIFE PRACTICE: Expanded due diligence offering for cell and gene therapy private equity portfolio. Optimized assets focused on MPM, Ovarian cancer, Pancreatic cancer, Colorectal cancer, TBNC, and other Solid Tumors and Hematological Malignancies. PAYER NETWORK ADEQUACY EXPANSION STRATEGY: Identified gaps in network coverage for large Blue Cross Blue Shield insurer. Developed/ implemented strategy allowing insurer to meet adequacy requirements in 94% of targeted counties in TX, IL, MN, OK, and NM.

Created commercial strategies and medical affairs engagement strategies for Life Sciences clients. Conducted competitive landscape analyses, evaluated client growth opportunities and capabilities, and developed financial, sales, and marketing insights to inform market access opportunities. Delivered commercial input into development decision, forecasting, launch tactics, and treatment patterns. CLIENT GROWTH OPPORTUNITIES: Guided/led customer insights, segmentation, value proposition, objectives roadmap, Go-To-Market plans, and channel strategy development. Researched epidemiology, patient flow, stakeholders, pricing, market access challenges, and in-pipeline competition enabling client to strengthen value perceptions and minimize competitive threat.

Basel, Baselstadt, Ch

Led projects within Oncology Division to develop pre-commercial medical strategy and launch assets for solid tumor cancers. Collaborated with Clinical Development Planning, BD&L, Finance, Clinical Operations, and Franchise to align strategy. Created strategy framework to accelerate clinical development and portfolio prioritization. INDUSTRY ENGAGEMENT: Partnered with internal Commercial, R&D, and HEOR areas, external patient advocacy groups, and secondary data providers to support benefit/risk analyses. KOL ENGAGEMENT: Led KOL engagement to support new Novartis melanoma cancer and breast cancer therapy delivering 2017 sales of $875M. NEW PRODUCT PLANNING: Supported planning for Piqray (solid tumor), PD-1 (immunotherapy), and Capmatinib (C-Met)). Developed TPP including Target Disease and Population, Treatment Approaches, Competition, Formulation (Target Manufacturing Profile), Primary Efficacy Endpoints, and Secondary Endpoint QOL. PRODUCT LAUNCH / INDICATION EXPANSION: Supported launch of Kisqali (breast cancer) and Tafinlar/Mekinist (Melanoma, lung cancer).

Rahway, New Jersey, Us

Led Brand HCP and Patient product acquisition and adherence strategy and launch across multiple disease areas and therapeutic products. Managed cross-functional team in late-stage asset Go-To-Market decisions. Directed commercial model transformation across disease and therapeutic business units in Merck Top 10 global markets (USA, EU-5, China, Japan, Brazil, S. Korea). DIGITAL TRANSFORMATION: Proposed digital transformation as global strategy to accelerate improvement in patient experience. Pharmacy implementation partnership captured 3-5% prescription lift on diabetes and cardiovascular brands – increasing brand revenues $40M. KEYTRUDA: Led growth strategy focusing on product optimal benefit with higher PD-L1 expression and championed commercial model transformation across USA and EU-5. PRODUCT GROWTH ENABLEMENT: Accelerated sales growth of multiple drugs including Cozaar/Hyzaar (hypertension), Singular (allergy), Asmanex (asthma), Vytorin (Cardiovascular), Maxalt (Migraine), and Keytruda (solid tumor cancer). Increased brand share of voice, prescription lift, and formulary coverage.

Masters Of Business Administration, Strategic Management

Bachelor Of Science - Bs